Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
78.5K
-
Shares change
-
+15.3K
-
Total reported value, excl. options
-
$4.91M
-
Value change
-
+$955K
-
Number of buys
-
2
-
Price
-
$62.60
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2023
3 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2023.
CRISPR Therapeutics AG - Common Stock (CRSP) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.5K shares
of 86M outstanding shares and own 0.09% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.54M shares), Capital International Investors (6.13M shares), T. Rowe Price Investment Management, Inc. (3.61M shares), Nikko Asset Management Americas, Inc. (3.37M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.37M shares), BlackRock Inc. (2.52M shares), FMR LLC (1.84M shares), STATE STREET CORP (1.75M shares), VANGUARD GROUP INC (1.59M shares), and NEA Management Company, LLC (1.59M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.